RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
RIVM to play greater role in tuberculosis control The Committee for Practical Tuberculosis Control (CPT) will be transferred per 1 January 2022 to the National Institute for Public Health and the Environment (RIVM) after a period of 70 years with KNCV Tuberculosis Foundation.
New WHO Collaborating Centre hosted by RIVM combines laboratory preparedness and biorisk RIVM has been designated WHO Collaborating Centre for Laboratory Preparedness and Response for High Threat Pathogens and Biorisk by the World Health Organization (WHO).
Increase in number of additives in tobacco products A total of 673 different types of additives are used by manufacturers in their tobacco products (cigarettes, cigars and pipe tobacco) and the number of additives used per tobacco product type incre
Metals in tobacco harmful to health Growing tobacco plants acquire metals from soil, fertilisers, and industrial pollution. Smoking liberates some of these metals from tobacco into smoke to be inhaled by the smoker and bystanders.
RIVM writes Novel Tobacco Products paper for WHO The World Health Organization (WHO) Tobacco Free Initiative (TFI) has just published a Report of the WHO Study Group on Tobacco Product Regulation (TobReg).
RIVM participates in large EU project to head up global fight against infectious diseases COMPARE, a large EU project intends to speed up the detection of, and response to disease outbreaks among humans and animals worldwide, through the use of new genome technology.